Modafinil Emona

Modafinil, the active ingredient in Modafinil Emona, is a eugeroic (wakefulness‑promoting agent) presented as an oral tablet for oral use. It treats excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder.\n\nGNH India supplies Modafinil Emona as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modafinil is a wakefulness‑promoting agent indicated for several sleep‑related disorders.\n\n- Narcolepsy: reduces daytime sleepiness and improves alertness.\n- Obstructive sleep apnea (excessive daytime sleepiness): helps maintain wakefulness in patients with residual sleepiness despite standard therapy.\n- Shift work sleep disorder: decreases sleepiness during scheduled work periods, supporting better performance.

Modafinil may cause a range of adverse reactions, from mild to serious.\n\nCommon Side Effects:\n- Headache\n- Nausea\n- Insomnia\n- Anxiety or nervousness\n- Dizziness\n- Dry mouth\n\nSerious or Rare Side Effects:\n- Severe skin reactions (e.g., Stevens‑Johnson syndrome)\n- Psychiatric disturbances (e.g., hallucinations, mania)\n- Cardiovascular events (e.g., hypertension, arrhythmia)\n- Allergic reactions (e.g., anaphylaxis)\n- Liver injury\n- Suicidal thoughts or behavior

Before prescribing Modafinil, clinicians should consider several safety factors.\n\n- Medical evaluation: assess cardiovascular status and history of cardiac disease.\n- Drug interactions: review concomitant medications that affect CYP3A4 metabolism.\n- Pregnancy and lactation: avoid use unless benefits clearly outweigh potential risks.\n- Psychiatric history: monitor for mood changes, psychosis, or suicidal ideation.\n- Renal/hepatic impairment: dose adjustment may be required based on organ function.\n- Store at ambient temperature: keep in the original container, protect from moisture and heat.

Modafinil can interact with several drug classes, requiring careful management.\n\nMajor Interactions (Avoid):\n- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma concentrations and risk of toxicity.\n- Central nervous system depressants (e.g., benzodiazepines, alcohol): may diminish wake‑promoting effects.\n- Monoamine oxidase inhibitors: risk of hypertensive crisis when combined.\n\nModerate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug levels.\n- Oral contraceptives: may decrease hormonal effectiveness, requiring additional contraception.\n- Antihypertensive agents: may enhance blood‑pressure‑lowering effects, necessitating monitoring.